Abstract:We followed a comprehensive computational strategy to understand and eventually predict the structure-activity relationship of thirty-three 1,3-disubstituted imidazole [1,5-α] pyrazine derivatives described as ATP competitive inhibitors of the IGF-1 receptor related to Ewing sarcoma. The quantitative structure-activity relationship model showed that the inhibitory potency is correlated with the molar volume, a steric descriptor and the net charge calculated value on atom C1 (q1) and N4 (q4) of the pharmacophore, all of them appearing to give a positive contribution to the inhibitory activity. According to experimental and calculated values, the most potent compound would be 3-[4-(azetidin-2-ylmethyl) cyclohexyl]-1-[3-(benzyloxy) phenyl] imidazo [1,5-α]pyrazin-8-amine (compound 23). Docking was used to guess important residues involved in the ATP-competitive inhibitory activity. It was validated by 200 ns of molecular dynamics (MD) simulation using improved linear interaction energy (LIE) method. MD of previously preferred structures by docking shows that the most potent ligand could establish hydrogen bonds with the ATP-binding site of the receptor, and the Ser979 and Ser1059 residues contribute favourably to the binding stability of compound 23. MD simulation also gave arguments about the chemical structure of the compound 23 being able to fit in the ATP-binding pocket, expecting to remain stable into it during the entire simulation and allowing us to hint the significant contribution expected to be given by electrostatic and hydrophobic interactions to the ligand-receptor complex stability. This computational combined strategy here described could represent a useful and effective prime approach to guide the identification of tyrosine kinase inhibitors as new lead compounds.

Multi-substituted 8-Aminoimidazo[1,2-a]pyrazines by Groebke–Blackburn–Bienaymé Reaction and Their Hsp90 Inhibitory Activity

Synthesis, Crystal Structures, Fluorescence and Xanthine Oxidase Inhibitory Activity of Pyrazole-Based 1,3,4-Oxadiazole Derivatives

Groebke Multicomponent Reaction and Subsequent Nucleophilic Aromatic Substitution for a Convenient Synthesis of 3,8-Diaminoimidazo[1,2-a]pyrazines As Potential Kinase Inhibitors.

Design, synthesis, and molecular docking studies of novel pyrazolyl 2-aminopyrimidine derivatives as HSP90 inhibitors

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Discovery of Potent N-(isoxazol-5-yl)amides As HSP90 Inhibitors.

Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.

Design, Synthesis, Biological Evaluation and Molecular Modeling of Novel 1H-Pyrazolo[3,4-d]pyrimidine Derivatives As BRAF(V600E) and VEGFR-2 Dual Inhibitors

New 3-[(4-hydroxy-6-methly-2(1h)-pyridinones)-3-yl]-4-substituted-(1h)1,2,4- Triazole-5-Thiones: Efficient Synthesis, X-Ray Crystallographic Analysis, and Antitumor Activity

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-B]pyridazine Derivatives As Mtor Inhibitors

Efficient Synthesis and Docking Studies of Novel Benzothiazole-Based Pyrimidinesulfonamide Scaffolds as New Antiviral Agents and Hsp90α Inhibitors

Access to Piperazine-Fused Pyrrolocarbazoles Enabled by Acid-Catalyzed Stereoselective Hydroarylation of Ynamide-Indoles and Subsequent Diels-Alder Reactions/Aromatizations

Identification of Novel Thiazolo[5,4-<i>b</i>]Pyridine Derivatives as Potent Phosphoinositide 3-Kinase Inhibitors

Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyri

Discovery of Pyrazolo[1,5- a ]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors

A computational strategy to understand structure-activity relationship of 1,3-disubstituted imidazole [1,5-α] pyrazine derivatives described as ATP competitive inhibitors of the IGF-1 receptor related to Ewing sarcoma

Design, Synthesis and Pharmacological Evaluation of ALK and Hsp90 Dual Inhibitors Bearing Resorcinol and 2,4-Diaminopyrimidine Motifs.

Synthesis and anticancer activities of imidazo [1,2-b] pyridazines as inhibitors of the mammalian target of rapamycin

Synthesis and evaluation of the antitumor activity of 2-amino-4-tetrahydroindazole-substituted benzamide derivatives as HSP90 inhibitors

Synthesis, Biological Assay in Vitro and Molecular Docking Studies of New Imidazopyrazinone Derivatives As Potential Dipeptidyl Peptidase IV Inhibitors.

Synthesis of 1-Hydroxy-10-methyl-pyrimido [1, 6-C][1, 3]oxazine and the Oxazepine Derivative, Structural Mimicry of Anti-Constrained Acyclic Thymidine